Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Insulin-Like Growth Factor I, Resistance To × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Rectal Neoplasms 1 Pleural Effusion 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Insulin-Like Growth Factor I, Resistance To 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

dalotuzumab 1 cixutumumab 1 Lapatinib 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00799240 2014-11-07

IMPACT

University of Kansas Medical Center

Phase 2 Completed

Insulin-Like Growth Factor I, Resistance To, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡